Human Alcohol Seeking Despite Aversion
| Status: | Recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 21 - 55 |
| Updated: | 11/16/2018 |
| Start Date: | April 1, 2018 |
| End Date: | March 1, 2022 |
| Contact: | Ann E Kosobud, PhD |
| Email: | akosobud@iupui.edu |
| Phone: | 3172740087 |
Prolonged alcohol use results in drinking despite resultant problems and adverse
consequences. The investigators propose to test a laboratory model of human seeking despite
aversion to use as an early marker of disease onset, and as a tool for study of its neural
functional substrates, and identification of effective treatments.
consequences. The investigators propose to test a laboratory model of human seeking despite
aversion to use as an early marker of disease onset, and as a tool for study of its neural
functional substrates, and identification of effective treatments.
The long-term goal for this project is to establish a model of alcohol seeking despite
aversion (SDA) as a platform for the laboratory testing of novel pharmacologic and behavioral
interventions that can be used among those with the highest risk, but who have yet to
progress to treatment-resistant drinking. The objective of this application is to test SDA
across multiple levels of analysis. The investigators consider SDA as an early marker of
alcohol use disorder progression that is related to lifetime drinking history, alcohol use
disorder risks, and brain physiology. The investigators have completed a pilot study
demonstrating that SDA can be objectively quantified via an intravenous alcohol
self-administration task, in which operant work for identical incremental alcohol rewards is
paired with aversive stimuli. This preliminary data supports the central hypotheses that
behavior in the SDA model is attributable to lifetime alcohol exposure, is related to alcohol
use disorder risk factors and phenotypes, and reflects alterations in neural system function.
In this project, SDA will be measured along with recent drinking history, negative
affect-based rash action (i.e. negative urgency, including action with respect to alcohol
use), and self-rating of the effects of alcohol. The rationale for this work is that it would
lead to the first objective, well-validated measure of SDA in humans.
aversion (SDA) as a platform for the laboratory testing of novel pharmacologic and behavioral
interventions that can be used among those with the highest risk, but who have yet to
progress to treatment-resistant drinking. The objective of this application is to test SDA
across multiple levels of analysis. The investigators consider SDA as an early marker of
alcohol use disorder progression that is related to lifetime drinking history, alcohol use
disorder risks, and brain physiology. The investigators have completed a pilot study
demonstrating that SDA can be objectively quantified via an intravenous alcohol
self-administration task, in which operant work for identical incremental alcohol rewards is
paired with aversive stimuli. This preliminary data supports the central hypotheses that
behavior in the SDA model is attributable to lifetime alcohol exposure, is related to alcohol
use disorder risk factors and phenotypes, and reflects alterations in neural system function.
In this project, SDA will be measured along with recent drinking history, negative
affect-based rash action (i.e. negative urgency, including action with respect to alcohol
use), and self-rating of the effects of alcohol. The rationale for this work is that it would
lead to the first objective, well-validated measure of SDA in humans.
Inclusion Criteria:
- Higher or lower lifetime alcohol drinking history
- Able to understand and complete questionnaires and procedures in English
- BMI between 18.5 and 32
- Willing and able to tolerate iv placement
- Right-handed (for fMRI Arm only)
Exclusion Criteria:
- Pregnant or breast-feeding
- Seeking or in treatment for substance use disorder or under court ordered abstinence
- Medications, medical disorders or conditions that could affect study outcome or
subject safety
- Positive urine drug screen for amphetamines/methamphetamines, barbiturates,
benzodiazepines, cocaine, opiates, or phencyclidine
- Positive breath alcohol (BrAC) reading on arrival at any study visit
- Actively suicidal (within previous year)
- Left-handed or ambidextrous (for fMRI Arm only)
We found this trial at
1
site
Indianapolis, Indiana 46122
Principal Investigator: Martin H Plawecki, MD
Phone: 317-948-6551
Click here to add this to my saved trials
